In this study, we integrated genomic, phosphorylation and drug sensitivity profiling to characterize p190-specific signature in CML in addition to hematopoietic progenitor cell line models. The gene discussed is CNTNAP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.